Document Type

Journal Article

Publication Title

Prostate Cancer and Prostatic Diseases

Publisher

Nature

School

School of Medical and Health Sciences / Exercise Medicine Research Institute / Centre for Precision Health / Centre for Exercise and Sports Science Research

RAS ID

43941

Funders

Movember Foundation National Health and Medical Research Council Centre for Research Excellence in Prostate Cancer Survivorship CAUL and its Member Institutions

Grant Number

NHMRC Number : APP1116334

Grant Link

http://purl.org/au-research/grants/nhmrc/1116334

Comments

Kim, J. S., Taaffe, D. R., Galvão, D. A., Hart, N. H., Gray, E., Ryan, C. J., . . . Newton, R. U. (2022). Exercise in advanced prostate cancer elevates myokine levels and suppresses in-vitro cell growth. Prostate Cancer and Prostatic Diseases. Advance online publication. https://doi.org/10.1038/s41391-022-00504-x

Abstract

Background: Altering the systemic milieu through exercise has been proposed as a potential mechanism underlying exercise-driven tumour suppression. It is not yet known whether men with advanced prostate cancer can elicit such adaptations following a program of exercise. The purpose is to examine myokine levels of serum acquired from metastatic castrate-resistant prostate cancer (mCRPC) patients recruited to the INTERVAL-GAP4 trial before and after 6 months of exercise and its tumour-suppressive effect. Methods: Twenty-five men with mCRPC (age = 74.7 ± 7.1 yrs) were randomised to supervised multimodal (aerobic and resistance) exercise (EX) or self-directed exercise control group (CON). Body composition was assessed using dual-energy x-ray absorptiometry (DXA), and fasting blood in a rested state was collected at baseline and at 6 months. Serum levels of myokines (SPARC, OSM, decorin, IGF-1, and IGFBP-3) were measured. Serum was applied to the prostate cancer cell line DU145, and growth was assessed for 72 h. Results: No significant change in body composition was observed. Adjusted serum OSM (P = 0.050) and relative OSM (P = 0.083), serum SPARC (P = 0.022) and relative SPARC (P = 0.025) increased in EX compared to CON. The area under curve (AUC) over 72 h showed a significant reduction in DU145 growth after applying post-intervention serum from the EX vs CON (P = 0.029). Conclusion: Elevated myokine expressions and greater tumour-suppressive effects of serum after 6 months of periodised and autoregulated supervised exercise was observed in men with mCRPC. Exercise-induced systemic changes may slow disease progression in men with advanced prostate cancer.

DOI

10.1038/s41391-022-00504-x

Creative Commons License

Creative Commons Attribution 4.0 License
This work is licensed under a Creative Commons Attribution 4.0 License.

Share

 
COinS